ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026
Preparation and antimicrobial activity of Mono-, Bis, and Tris-4,9-Dihydroxy-7,7-Dimethyl-5-(mono-substituted-aryl)-Hexahydro-Indeno[1,2-b]Indole-9,10-Dione derivatives.
Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, indeno[1,2-b]indolone scaffolds were assembled through an operationally simple, aqueous Cu(OAc)₂ catalyzed three-component domino reaction furnishing mono-, bis- and tris-analogues in 68-95% isolated yields under mild conditions (60-85 °C, ≤ 150 min). Antimicrobial profiling (MIC & IC₅₀, 125 µg disc) against six clinically relevant strains revealed a steep electronic gradient: electron-withdrawing (EW) substituents usually drive sub-μg mL⁻¹ potency, whereas electron-donating (ED) groups abolish activity (>100 μg mL⁻¹). The meta-chloro mono-derivative 19g reaches 0.06 μg mL⁻¹ against (Bacillus subtilis) B. subtilis and (Escherichia coli) E. coli (equipotent to gentamicin, 2-fold above ampicillin), while the tris-expanded 23 breaches 0.015 μg mL⁻¹ 9-fold superior to ampicillin and the first indeno-indolone to match reference antibiotics without surpassing them. Mechanistic cues (ROS burst & DNA-gyrase docking) support a dual-mode action: membrane disruption plus topoisomerase inhibition. The scalable, metal-light protocol and clear EW > push-pull > ED ranking offer immediate lead-optimization handles to close the remaining 4-8-fold fungal gap versus Amphotericin B and to attenuate Gram-negative efflux, positioning 23 as a credible next-generation antibiotic candidate.
Indexed as
Identifiers
42446655What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.